Clinical Trials | December 27, 2025
InnoCare Pharma gets green light for Phase II trial of oral lupus drug
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Subscribe To Our Newsletter & Stay Updated
